본문 바로가기 주메뉴 바로가기

제품소개

제품상세페이지

Proteogenix

[Proteogenix] Human CD20/MS4A1 recombinant protein

Cat-No. PX-P6274


Proteogenix는 Primary Antibody Biosimilar - Research Grade 

제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.




제품 설명 


Human CD20/MS4A1 recombinant protein

  



제품 번호

 

PX-P6274

 



제품 특징


Product nameHuman CD20/MS4A1 recombinant protein
Uniprot IDP11836
Origin speciesHomo sapiens (Human)
Expression systemProkaryotic expression
Molecular weight19.58 kDa
Protein delivered with Tag?N-Terminal His & N-Terminal Trx Tags
Purity estimated>85% by SDS-PAGE
BufferLyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Delivery conditionDry Ice
Storage condition4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection)
BrandProteoGenix
Host speciesEscherichia coli (E.coli)
ApplicationsELISA,WB
Fragment TypeIle143-Ser188
Aliases /SynonymsB-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20
ReferencePX-P6274
NoteFor research use only


Description of Human CD20/MS4A1 recombinant protein

General information on Human CD20/MS4A1 recombinant protein

Structure of Human CD20/MS4A1 Recombinant Protein

The human CD20/MS4A1 recombinant protein is a type I membrane protein composed of a single extracellular loop, a single transmembrane domain, and a cytoplasmic tail. It is expressed on the surface of B-cells and is involved in B-cell activation and proliferation.

Activity of Human CD20/MS4A1 Recombinant Protein

The activity of the human CD20/MS4A1 recombinant protein is mediated by its interaction with other proteins, such as CD19 and CD21, which are involved in B-cell activation and proliferation. The CD20/MS4A1 protein is also involved in the regulation of B-cell differentiation and maturation.

Application of Human CD20/MS4A1 Recombinant Protein

The human CD20/MS4A1 recombinant protein is a promising target for the development of antibody-drug conjugates for the treatment of B-cell malignancies. Antibodies targeting the CD20/MS4A1 protein have been successfully used in clinical trials, demonstrating their potential as an effective treatment for various B-cell malignancies.




QC & Validation Data


Ocrelizumab Biosimilar - Anti-MS4A1, CD20 mAb binds to Human CD20/MS4A1 recombinant protein in indirect ELISA Assay

Immobilized Human CD20/MS4A1 recombinant protein (cat. No.PX-P6274) at 0.5µg/mL (100µL/well) can bind to Ocrelizumab Biosimilar - Anti-MS4A1, CD20 mAb (cat. No.PX-TA1162) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450




ProteoGenix의 모든 제품들을 만나보세요!

 

Proteogenix - Exclusive Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"